Letrozole (Femara): Mylan settled with innovator

Mylan pharma announced in a press release Here, that Mylan have settled with innovator Nowartis with respect to their pending patent litigation on Letrozole tablets pending at New Jersy District court since June, 2006. Mylan in a bid to market generic version of Novartis's Femara (Letrozole) tablets 2.5 mg, filed ANDA in 2006. Subsequently, innovator sued Mylan in New Jersy District court for the infringement of US4978672 (Expiry: June 3,2011): Which covers Alpha-heterocyclc substituted tolunitriles as product (including Letrozole)

Under the agreement, Mylan is provided a patent license that will enable the company to market Letrozole Tablets, 2.5 mg, prior to the expiration of '672 patent. Additional terms related to the settlement remain confidential, and the agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

Accordingly, an early generic launch by Mylan is on the cards.

Irinotecan Hydrochloride: ScinoPharm got novel polymorph patent

ScinoPharm, an active pharmaceutical ingredient (API) specialist, has been granted US7435818 which covers a crystalline form of Irinotecan hydrochloride having a powder X-ray diffraction pattern with peaks at 20.3956.+-.0.2, 22.2950.+-.0.2, 12.0744.+-.0.2, 8.4800.+-.0.2, and 11.8306.+-.0.2 degrees in two theta. The said patent covers crystalline form I, II, III and IV of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin monohydrochloride trihydrate (irinotecan hydrochloride).

Details are Here